Updated Understanding of Autoimmune Lymphoproliferative Syndrome (ALPS)

Clinical Reviews in Allergy and Immunology

Volumn 50, Issue 1, 2016, Pages 55-63

  Li, Pu ^a   Huang, Ping ^a   Yang, Ye ^b   Hao, Mu ^b,c   Peng, Hongwei ^a   Li, Fei ^a  

^a NANCHANG UNIVERSITY   (China)

^b UNIVERSITY OF IOWA   (United States)

^c INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

Author keywords

Autoimmune lymphoproliferative syndrome; Cytopenia; Double negative T cells; FAS; Gene mutation; Treatment

Indexed keywords

ARSENIC TRIOXIDE; CD27 ANTIGEN; CD28 ANTIGEN; CD45RA ANTIGEN; CD57 ANTIGEN; FAS LIGAND; HISTONE DEACETYLASE INHIBITOR; HLA DR ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 4; INTERLEUKIN 5; MICRORNA; MICRORNA 146; MYCOPHENOLATE MOFETIL; PENTOSTATIN; PERFORIN; PYRIMETHAMINE; RAPAMYCIN; RITUXIMAB; SULFADOXINE; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

ANTIGEN EXPRESSION; APOPTOSIS ASSAY; AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME; BONE MARROW BIOPSY; BONE MARROW TRANSPLANTATION; CLINICAL FEATURE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG TOLERABILITY; GENE EXPRESSION; GENETIC ANALYSIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HETEROZYGOSITY; HISTOPATHOLOGY; HOMOZYGOSITY; HUMAN; LONG TERM SURVIVAL; LYMPH NODE BIOPSY; LYMPHOCYTE COUNT; MAINTENANCE THERAPY; MOLECULAR PATHOLOGY; NONHUMAN; PROTEIN EXPRESSION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; ANIMAL; DIFFERENTIAL DIAGNOSIS; METABOLISM; MULTIMODALITY CANCER THERAPY; TREATMENT OUTCOME;

ANIMALS; AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME; BIOMARKERS; COMBINED MODALITY THERAPY; DIAGNOSIS, DIFFERENTIAL; HUMANS; TREATMENT OUTCOME;

EID: 84957428775     PISSN: 10800549     EISSN: 15590267     Source Type: Journal    
DOI: 10.1007/s12016-015-8466-y     Document Type: Review

References (55)

1. Rao VK, Oliveira JB (2011) How I treat autoimmune lymphoproliferative syndrome. Blood 118:5741–5751
2. Canale VC, Smith CH (1967) Chronic lymphadenopathysimulating malignant Lymphoma.J. Paediatr 70:891–899
3. Sneller MC, Straus SE, Jaffe ES et al (1992) A novel lymphoproliferative⁄autoimmune syndrome resembling murinelpr⁄gld disease. J Clin Invest 90:334–341
4. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Naqata S (1992) Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356:314–317
5. Takahashi T, Tanaka M, Brannan CI et al (1994) Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 76:969–976
6. Rieux-Laucat F, Le Deist F, Hivroz C et al (1995) Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 268:1347–1349
7. Fisher GH, Rosenberg FJ, Straus SE et al (1995) Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 81:935–946
8. Worth A, Thrasher AJ H, Gaspar HB (2006) Autoimmune lymphoproliferative syndrome: molecular basis of disease and clinical phenotype. Br J Haematol 133:124–140
9. Hansford JR, Pal M, Poplawski N et al (2013) In utero and early postnatal presentation of autoimmune lymphoproliferative syndrome in a family with a novel FAS mutation. Haematologica 98:e38–e39
10. Deutsch M, Tsopanou E, Dourakis SP (2004) The autoimmune lymphoproliferative syndrome (Canale-Smith) in adulthood. Clin Rheumatol 23:43–44
11. der Werff V, ten Bosch J (2003) Autoimmune lymphoproliferative syndrome: etiology, diagnosis, and management. Paediatr Drugs 5:185–193
12. Teachey DT, Seif AE, Grupp SA (2010) Advances in the management and understanding of autoimmune lymphoproliferative syndrome (ALPS). Br J Haematol 148:205–216
13. Jackson CE, Puck JM (1999) Autoimmune lymphoproliferative syndrome, a Disorder of apoptosis. Curr Opin Pediatr 11:521–527
14. Straus SE, Jaffe ES, Puck JM et al (2001) The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. Blood 98:194–200
15. Teachey DT, Manno CS, Axsom KM et al (2005) Unmasking Evans syndrome: T-cell phenotype and apoptotic response reveal autoimmune lymphoproliferative syndrome (ALPS). Blood 105:2443–2448
16. Madkaikar M, Mhatre S, Gupta M, Ghosh K (2011) Advances in autoimmune lymphoproliferative syndromes. Eur J Haematol 87:1–9
17. Teachey DT (2012) New advances in the diagnosis and treatment of autoimmune lymphoproliferative syndrome. Curr Opin Pediatr 24:1–8
18. Oliveira JB, Bleesing JJ, Dianzani U et al (2010) Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome: report from the 2009 NIH International Workshop. Blood 116:e35–e40
19. Bleesing JJ, Brown MR, Novicio C (2002) A composite picture of TcR alpha/ beta (+) CD4(−)CD8(+) T Cells (alpha/beta-DNTCs) in humans with autoimmune lymphoproliferative syndrome. Clin Immunol 104:21–30
20. Bleesing JJ, Brown MR, Dale JK et al (2001) TcR-alpha/beta (+) CD4(−)CD8(+)T cells in humans with the autoimmune lymphoproliferative syndrome express a novel CD45 isoform that is analogous to murine B220 and represents a marker of altered O-glycan biosynthesis. Clin Immunol 100:314–324
21. Fischer K, Voelkl S, Heymann J et al (2005) Isolation and characterization of human antigen-specific TCR alpha beta + CD4(−)CD8(+) double-negative regulatory T cells. Blood 105:2828–2835
22. Muppidi J, Porter M, Siegel RM (2004) Measurement of apoptosis and other forms of cell death. Curr Protoc Immunol. Chapter 3:Unit 3.17
23. Holzelova E, Vonarbourg C, Stolzenberg MC et al (2004) Autoimmune lymphoproliferative syndrome with somatic Fas mutations. N Engl J Med 351:1409–1418
24. Straus SE, Sneller M, Lenardo MJ, Puck JM, Strober W (1999) An inherited disorder of lymphocyte apoptosis: the autoimmune lymphoproliferative syndrome. Ann Intern Med 130:591–601
25. Caminha I, Fleisher TA, Hornung RL et al (2010) Using biomarkers to predict the presence of FAS mutations in patients with features of the autoimmune lymphoproliferative syndrome. J Allergy Clin Immunol 125:946–949
26. Bowen RA, Dowdell KC, Dale JK et al (2012) Elevated vitamin B12 levels in autoimmune lymphoproliferative syndrome attributable to elevated haptocorrin in lymphocytes. Clin Biochem 45:490–492
27. Neven B, Magerus-Chatinet A, Florkin B et al (2011) A survey of 90 patients with autoimmune lymphoproliferative syndrome related to TNFRSF6 mutation. Blood 118:4798–4807
28. Campagnoli MF, Garbarini L, Quarello P et al (2006) The broad spectrum of autoimmune lymphoproliferative disease:molecular bases, clinical features and long-term follow-up in 31 patients. Haematologica 91:538–541
29. Price S, Shaw PA, Seitz A et al (2014) Natural history of autoimmune lymphoproliferative syndrome associated with FAS gene mutations. Blood 123:1989–1999
30. Bleesing JJ, Straus SE, Fleisher TA (2000) Autoimmune lymphoproliferative syndrome. A human disorder of abnormal lymphocyte survival. Pediatr Clin North Am 47:1291–1310
31. Rao VK, Straus SE (2006) Causes and consequences of the autoimmune lymphoproliferative syndrome. Hematology 11:15–23
32. Chun HJ, Zheng L, Ahmad M et al (2002) Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency. Nature 419:395–399
33. Shah S, Wu E, Rao VK, Tarrant TK (2014) Autoimmune lymphoproliferative syndrome: an update and review of the literature. Curr Allergy Asthma Rep 14:462
34. Simesen de Bielke MG, Yancoski J, Rocco C et al (2012) A missense mutation in the extracellular domain of Fas: the most common change in Argentinean patients with autoimmune lymphoproliferative syndrome represents a founder effect. J Clin Immunol 32:1197–1203
35. Tadaki H, Saitsu H, Kanegane H et al (2011) Exonic deletion of CASP10 in a patient presenting with systemic juvenile idiopathic arthritis, but not with autoimmune lymphoproliferative syndrome type IIa. Int J Immunogenet 38:287–293
36. Aricò M, Boggio E, Cetica V et al (2013) Variations of the UNC13D gene in patients with autoimmune lymphoproliferative syndrome. PLoS One 8:e68045
37. Takagi M, Shinoda K, Piao J et al (2011) Autoimmune lymphoproliferative syndrome-like disease with somatic KRAS mutation. Blood 117:2887–2890
38. Niemela JE, Lu L, Fleisher TA et al (2011) Somatic KRAS mutations associated with a human nonmalignant syndrome of autoimmunity and abnormal leukocyte homeostasis. Blood 117:2883–2886
39. Guo Q, Zhang J, Li J et al (2013) Forced miR-146a expression causes autoimmune lymphoproliferativesyndrome in mice via downregulation of Fas in germinal center B cells. Blood 121:4875–4883
40. Dowdell KC, Niemela JE, Price S et al (2010) Somatic FAS mutations are common in patients with genetically undefined autoimmune lymphoproliferative syndrome. Blood 115:5164–5169
41. Oliveira JB, Bidere N, Niemela JE et al (2007) NRAS mutation causes a human autoimmune lymphoproliferative syndrome. Proc Natl Acad Sci U S A 104:8953–8958
42. Dianzani U, Bragardo M, DiFranco D et al (1997) Deficiency of the Fas apoptosis pathway without Fas gene mutations in pediatric patients with autoimmunity/lymphoproliferation. Blood 89:2871–2879
43. Ramenghi U, Bonissoni S, Migliaretti G et al (2000) Deficiency of the Fas apoptosis pathway without Fas gene mutations is a familial trait predisposing to development of autoimmune diseases and cancer. Blood 95:3176–3182
44. Snow AL, Marsh RA, Krummey SM et al (2009) Restimulation-induced apoptosis of T cells is impaired in patients with X-linked lymphoproliferative disease caused by SAP deficiency. J Clin Invest 119:2976–2989
45. Rudman Spergel A, Walkovich K, Price S et al (2013) Autoimmune lymphoproliferative syndrome misdiagnosed as hemophagocytic lymphohistiocytosis. Pediatrics 132:e1440–e1444
46. Nomura K, Kanegane H, Otsubo K et al (2011) Autoimmune lymphoproliferative syndrome mimicking chronic active Epstein-Barr virus infection. Int J Hematol 93:760–764
47. Rao VK, Price S, Perkins K et al (2009) Use of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS). Pediatric Blood Cancer 52:847–852
48. Cooper N, Davies EG, Thrasher AJ (2009) Repeated courses of rituximab for autoimmune cytopenias may precipitate profound hypogammaglobulinaemia requiring replacement intravenous immunoglobulin. Br J Haematol 146:120–122
49. Neven B, Bruneau J, Stolzenberg MC et al (2014) Defective anti-polysaccharide response and splenic marginal zone disorganization in ALPS patients. Blood 124:1597–1609
50. Arora S, Singh N, Chaudhary GK, John MJ (2011) Autoimmune lymphoproliferative syndrome: response to mycophenolate mofetil and pyrimethamine/sulfadoxine in a 5-year-old child. Indian J Hematol Blood Transfus 27:101–103
51. Teachey DT, Greiner R, Seif A et al (2009) Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome. Br J Haematol 145:101–106
52. Bajwa R, Savelli S, Gross T (2011) Pentostatin for treatment of refractory autoimmune lymphoproliferative syndrome. Pediatr Blood Cancer 57:336–337
53. Rao VK, Dugan F, Dale JK et al (2005) Use of mycophenolate mofetil for chronic, refractory immune cytopenias in children with autoimmune lymphoproliferative syndrome. Br J Haematol 129:534–538
54. Bobé P, Bonardelle D, Benihoud K et al (2006) Arsenic trioxide: a promising novel therapeutic agent for lymphoproliferative and autoimmune syndromes in MRL/lpr mice. Blood 108:3967
55. Dowdell KC, Pesnicak L, Hoffmann V et al (2009) Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, diminishes lymphoproliferation in the Fas deficient MRL/lpr(−/−) murine model of autoimmune lymphoproliferative syndrome (ALPS). Exp Hematol 37:487–494